Moderna's Cancer Vaccine Cut Recurrence Risk 42% — and the Stock Still Fell

Moderna and Merck's intismeran plus Keytruda cut melanoma recurrence or death risk by 42% over two years, yet Moderna's stock dropped 17.6% on a broken-embargo release.